SCPS Stock Price, Scopus BioPharma Inc. Quote, Chart

0

SCPS Stock Price

View Fullscreen

SCPS RSI Chart

SCPS Valuation

SCPS Price/Earnings (Trailing)

SCPS Profitability

Return on Equity

-42.3K%

Return on Assets

-1.8K%

SCPS Fundamentals

SCPS Earnings

Earnings (TTM)

-8.9M

Breaking Down SCPS Revenue

Trailing 12 Months

-100%

How does SCPS drawdown profile look like?

SCPS Financial Health

Current Ratio

0.05

SCPS Investor Care

Shares Dilution (1Y)

99.51%

Tracking the Latest Insider Buys and Sells of Scopus BioPharma Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 27, 2021	greenspan ira scott	bought	541	4.92	110	executive committee chairman
Aug 27, 2021	lamstein joshua r	bought	1,000	5.00	200	chairman
Aug 27, 2021	greenspan ira scott	bought	3,934	4.98	790	executive committee chairman
Aug 26, 2021	lamstein joshua r	bought	980	4.9	200	chairman
Aug 24, 2021	greenspan ira scott	bought	232	4.65	50.00	executive committee chairman
Aug 23, 2021	greenspan ira scott	bought	2,205	4.41	500	executive committee chairman
Aug 20, 2021	greenspan ira scott	bought	1,692	4.23	400	executive committee chairman
Aug 19, 2021	lamstein joshua r	bought	3,232	4.04	800	chairman
Aug 19, 2021	greenspan ira scott	bought	8,080	4.04	2,000	executive committee chairman
Aug 18, 2021	greenspan ira scott	bought	4,270	4.27	1,000	executive committee chairman

Which funds bought or sold SCPS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	FSA Wealth Management LLC	unchanged	-	-	-	-%

Are Funds Buying or Selling SCPS?

Are funds buying SCPS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SCPS

No. of Funds

Unveiling Scopus BioPharma Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 15, 2022	armistice capital, llc	9.96%	2,100,000	SC 13G

Recent SEC filings of Scopus BioPharma Inc.

View All Filings

Date Filed	Form Type	Document
Feb 09, 2024	1-Z	1-Z

Scopus BioPharma Inc. News

Latest updates

Scopus BioPharma Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet													(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-69.0%	498	1,603	392	416	1,673	4,608	8,188	4,032	6,808	8,627	1,974	1,240	772
Current Assets	-69.0%	496	1,601	390	413	1,670	4,604	8,185	4,028	6,805	8,625	1,972	1,237	768
Cash Equivalents	-74.2%	362	1,401	125	311	1,156	3,975	7,943	3,632	6,261	8,256	1,832	421	37.00
Net PPE	-16.4%	2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	4.00	2.00	2.00	3.00	4.00
Current Liabilities	18.1%	11,002	9,313	7,454	-	-	-	4,170	2,237	8,792	4,479	3,805	3,789	855
LT Debt, Current	-	-	-	-	-	-	-	-	-	2,803	2,543	2,284	2,024	-
Shareholder's Equity	-	-	-	-	-	21.00	21.00	21.00	1,794	-	4,148	-	-	-
Retained Earnings	-4.7%	-58,131	-55,514	-53,064	-51,334	-49,435	-46,115	-41,455	-34,936	-33,535	-17,907	-14,501	-13,450	-3,639
Additional Paid-In Capital	0.1%	48,616	48,543	46,518	45,812	45,728	45,633	45,538	38,279	33,095	23,587	14,224	12,424	3,578
Shares Outstanding	0%	39,584	39,584	21,094	21,094	21,094	21,094	21,094	16,551	18,094	15,337	14,578	13,121	-
Minority Interest	-38.0%	-1,052	-762	-497	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,100	-	4,900	-	18,700	-	60,300	-	119,600	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	-32.8%	-1,009	-759	-421	-851	-2,875	-3,977	-4,148	-2,516	-1,962	-2,796	-919	-661	-818	-126	-	-
Share Based Compensation	0%	78.00	78.00	78.00	84.00	95.00	95.00	144	154	188	183	90.00	60.00	60.00	60.00	-	-
Cashflow From Financing	-102.2%	-44.68	2,019	242	-	-	-	8,480	-104	-19.12	9,200	2,361	332	1,579	81.00	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SCPS Income Statement

2023-06-30

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
General and administrative	$ 935,860	$ 2,670,135	$ 2,006,594	$ 6,961,801
Research and development	1,992,998	649,468	3,601,920	1,018,576
Total operating expenses	2,928,858	3,319,603	5,608,514	7,980,377
Net loss	(2,928,858)	(3,319,603)	(5,608,514)	(7,980,377)
Net loss attributable to non-controlling interest (deficit)	(312,305)		(542,140)
Net loss attributable to Scopus BioPharma Inc.	(2,616,553)	(3,319,603)	(5,066,374)	(7,980,377)
Comprehensive income:
Foreign currency translation adjustment	16,756	56,754	35,185	74,620
Total comprehensive loss attributable to Scopus BioPharma Inc.	$ (2,599,797)	$ (3,262,849)	$ (5,031,189)	$ (7,905,757)
Net loss per common share attributable to Scopus BioPharma Inc.:
Net loss per common share attributable to Scopus BioPharma, Inc., Basic	$ (0.07)	$ (0.16)	$ (0.14)	$ (0.38)
Net loss per common share attributable to Scopus BioPharma, Inc., Diluted	$ (0.07)	$ (0.16)	$ (0.14)	$ (0.38)
Weighted-average common shares outstanding:
Weighted-average common shares outstanding, Basic	39,742,505	21,094,264	35,081,943	21,094,264
Weighted-average common shares outstanding, Diluted	39,742,505	21,094,264	35,081,943	21,094,264

SCPS Balance Sheet

2023-06-30

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash	$ 362,097	$ 124,575
Prepaid expenses and other current assets	133,757	265,425
Total current assets	495,854	390,000
Property and equipment, net	1,700	2,265
Total assets	497,554	392,265
Current liabilities:
Accounts payable and accrued expenses	10,908,917	7,201,926
Other current liabilities	93,178	252,508
Total current liabilities	11,002,095	7,454,434
COMMITMENTS AND CONTINGENCIES
Stockholders' equity (deficit):
Preferred stock, $0.001 par value; 20,000,000 shares authorized; zero shares issued and outstanding
Common stock, $0.001 par value; 50,000,000 shares authorized; 39,784,264 and 21,094,264 issued and outstanding at June 30, 2023 and December 31, 2022, respectively	39,784	21,094
Additional paid-in capital	48,615,546	46,518,455
Stock subscriptions receivable	(5,962)	(33,950)
Accumulated deficit	(58,131,350)	(53,064,975)
Accumulated other comprehensive income (loss)	30,231	(4,954)
Total Scopus BioPharma Inc. stockholders' deficit	(9,451,751)	(6,564,330)
Noncontrolling interest (deficit)	(1,052,790)	(497,839)
Total stockholders' deficit	(10,504,541)	(7,062,169)
Total liabilities and stockholders' deficit	$ 497,554	$ 392,265

About Scopus BioPharma Inc.

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

CEO	Dr. Alan D. Horsager Ph.D.
WEBSITE	https://scopusbiopharma.com
INDUSTRY	Biotechnology
EMPLOYEES	13

Scopus BioPharma Inc. Frequently Asked Questions

What is the ticker symbol for Scopus BioPharma Inc.? What does SCPS stand for in stocks?

SCPS is the stock ticker symbol of Scopus BioPharma Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Scopus BioPharma Inc. (SCPS)?

As of Fri May 17 2024, market cap of Scopus BioPharma Inc. is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SCPS stock?

You can check SCPS's fair value in chart for subscribers.

What is the fair value of SCPS stock?

You can check SCPS's fair value in chart for subscribers. The fair value of Scopus BioPharma Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Scopus BioPharma Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SCPS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Scopus BioPharma Inc. a good stock to buy?

The fair value guage provides a quick view whether SCPS is over valued or under valued. Whether Scopus BioPharma Inc. is cheap or expensive depends on the assumptions which impact Scopus BioPharma Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SCPS.